Yubo International Biotech Limited
Yubo International Biotech Limited, through its subsidiaries, focuses on the research, development, and application of endometrial stem cells. The company offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting ser… Read more
Yubo International Biotech Limited (YBGJ) - Total Liabilities
Latest total liabilities as of September 2025: $2.56 Million USD
Based on the latest financial reports, Yubo International Biotech Limited (YBGJ) has total liabilities worth $2.56 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yubo International Biotech Limited - Total Liabilities Trend (2002–2024)
This chart illustrates how Yubo International Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yubo International Biotech Limited Competitors by Total Liabilities
The table below lists competitors of Yubo International Biotech Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Core Assets Corp
OTCQB:CCOOF
|
USA | $2.68 Million |
|
Signet International Holdings Inc
PINK:AQPW
|
USA | $387.29K |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$4.62 Million |
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
USA | $4.40 Million |
|
2U, Inc.
PINK:TWOUQ
|
USA | $1.20 Billion |
|
Kedaung Indah Can Tbk
JK:KICI
|
Indonesia | Rp100.38 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $8.32 Billion |
|
Anagenics Ltd
AU:AN1
|
Australia | AU$1.82 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Yubo International Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yubo International Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yubo International Biotech Limited (2002–2024)
The table below shows the annual total liabilities of Yubo International Biotech Limited from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.83 Million | +37.64% |
| 2023-12-31 | $3.51 Million | +20.49% |
| 2022-12-31 | $2.91 Million | -38.24% |
| 2021-12-31 | $4.72 Million | +269.42% |
| 2020-12-31 | $1.28 Million | -29.00% |
| 2019-12-31 | $1.80 Million | +7.85% |
| 2018-12-31 | $1.67 Million | +9.66% |
| 2017-12-31 | $1.52 Million | +10.54% |
| 2016-12-31 | $1.38 Million | +8.18% |
| 2015-12-31 | $1.27 Million | +2.91% |
| 2014-12-31 | $1.24 Million | +11.35% |
| 2013-12-31 | $1.11 Million | +20.52% |
| 2012-12-31 | $921.00K | +13.28% |
| 2011-12-31 | $813.00K | +11.52% |
| 2010-12-31 | $729.00K | +17.96% |
| 2009-12-31 | $618.00K | +17.27% |
| 2008-12-31 | $527.00K | +34.44% |
| 2007-12-31 | $392.00K | +23.27% |
| 2006-12-31 | $318.00K | +26.19% |
| 2005-12-31 | $252.00K | -25.44% |
| 2004-12-31 | $338.00K | -27.16% |
| 2003-12-31 | $464.00K | -42.36% |
| 2002-12-31 | $805.00K | -- |